Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
What happened
The Food and Drug Administration (FDA) is announcing a public hearing on September 14, 2026, to discuss the potential future therapeutic use of psychedelic drugs. This hybrid meeting seeks feedback and perspectives on using psychedelic drug products in supervised and supportive settings. The public can register to attend or present by August 21, 2026, and submit comments until October 5, 2026. This action was signed by Donald Trump.
Why it matters
This hearing allows the public and stakeholders to share their views on how psychedelic drugs could be used for medical treatments. The information gathered will help the FDA understand the issues and considerations for potentially incorporating these substances into therapy. It could influence future policies and guidelines for psychedelic drug development and use.
Who it affects
- ›Patients seeking new therapeutic options
- ›Healthcare providers and researchers
- ›Pharmaceutical companies
- ›Federal partners and agencies
- ›The general public interested in drug policy
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.